Odyssey Therapeutics, Inc. (ODTX)
NASDAQ: ODTX · Real-Time Price · USD
17.39
-0.23 (-1.31%)
At close: May 18, 2026, 4:00 PM EDT
18.38
+0.99 (5.69%)
After-hours: May 18, 2026, 7:26 PM EDT
Odyssey Therapeutics Revenue
In the year 2025, Odyssey Therapeutics had annual revenue of $2.98M, down -33.45%. Odyssey Therapeutics had revenue of $287.00K in the quarter ending December 31, 2023.
Revenue (ttm)
$2.98M
Revenue Growth
-33.45%
P/S Ratio
275.66
Revenue / Employee
$29,760
Employees
100
Market Cap
820.36M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.98M | -1.50M | -33.45% |
| Dec 31, 2024 | 4.47M | 3.44M | 331.24% |
| Dec 31, 2023 | 1.04M | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionODTX News
- 10 days ago - Biotech firm Odyssey valued at $899.9 million as shares rises in Nasdaq debut - Reuters
- 11 days ago - Biotech firm Odyssey raises $279 million in upsized US IPO - Reuters
- 11 days ago - Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering - GlobeNewsWire
- 14 days ago - Biotech firm Odyssey targets $810 million in valuation in US IPO - Reuters
- 2 months ago - Odyssey Therapeutics Appoints H. Martin Seidel, Ph.D. - Business Wire
- 4 months ago - Odyssey Therapeutics Appoints Jolie M. Siegel as Executive Vice President, General Counsel - Business Wire
- 6 months ago - Odyssey Therapeutics Appoints Dennis Dean, Ph.D., as Executive Vice President, Head of Non-Clinical Development - Business Wire
- 7 months ago - Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to Its Board of Directors - Business Wire